UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 ASHLAND INC. (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Num ...

Ashland (NYSE:ASH) Q1 2026 Earnings call February 03, 2026 09:00 AM ET Company ParticipantsAlessandra Faccin Assis - SVP, Life Sciences and IntermediatesDago Caceres - SVP, Specialty AdditivesGuillermo Novo - Chair and CEOJim Minicucci - SVP, Personal CareJosh Spector - Director of Equity ResearchMichael Sison - Managing DirectorSandy Klugman - Director of Investor RelationsStephen Haynes - VP in Equity ResearchWilliam Whitaker - CFOConference Call ParticipantsBhavesh Lodaya - Senior Research AnalystChris P ...

Ashland (NYSE:ASH) Q1 2026 Earnings call February 03, 2026 09:00 AM ET Company ParticipantsAlessandra Faccin Assis - SVP, Life Sciences and IntermediatesDago Caceres - SVP, Specialty AdditivesGuillermo Novo - Chair and CEOJim Minicucci - SVP, Personal CareJosh Spector - Director of Equity ResearchMichael Sison - Managing DirectorSandy Klugman - Director of Investor RelationsStephen Haynes - VP in Equity ResearchWilliam Whitaker - CFOConference Call ParticipantsBhavesh Lodaya - Senior Research AnalystChris P ...

Ashland (NYSE:ASH) Q1 2026 Earnings call February 03, 2026 09:00 AM ET Speaker13Hello, and thank you for standing by. Welcome to Ashland's first quarter 2026 earnings conference call and webcast. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask the question during the session, you will need to press star one one on your telephone. You would then hear an automated message advising your hand is raised. To withdraw y ...

earnings conference call first quarter fiscal 2026 — February 3, 2026 Forward-Looking Statements — This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "s ...

Core Insights - Ashland Global Holdings Inc. reported a loss from continuing operations of $14 million or 30 cents per share for Q1 fiscal 2026, an improvement from a loss of $166 million or $3.51 per share in the same quarter last year [1] - Adjusted earnings were 26 cents per share, slightly down from 28 cents in the prior year, but exceeded the Zacks Consensus Estimate of 23 cents [1] Financial Performance - Sales decreased by 5% year over year to $386 million, missing the Zacks Consensus Estimate of $408.3 million [2] - The decline in sales was attributed to the divestiture of the Avoca business, which reduced revenue by approximately $10 million, and weaker demand in sectors such as coatings, construction, personal care, and industrials, along with modest pricing pressure [2] Segment Performance - Life Sciences segment sales increased by 4% year over year to $139 million, though it fell short of the Zacks Consensus Estimate of $146 million, driven by resilient demand in pharma applications [3] - Personal Care segment sales declined by 8% year over year to $123 million, missing the Zacks Consensus Estimate of $132 million, primarily due to portfolio optimization linked to the Avoca divestiture [4] - Specialty Additives segment sales fell by 11% year over year to $102 million, missing the Zacks Consensus Estimate of $111 million, due to weak demand in coatings in China and increased competition [5] - Intermediates segment sales decreased by 6% year over year to $31 million, slightly beating the consensus estimate of $30.26 million, mainly due to lower pricing across the BDO value chain [6] Financial Position - Cash and cash equivalents at the end of the quarter were $304 million, reflecting a sequential increase of approximately 41.4% [7] - Long-term debt stood at $1,387 million, up roughly 0.2% from the previous quarter [7] Outlook - For fiscal 2026, Ashland anticipates sales between $1.835 billion and $1.905 billion, with adjusted EBITDA projected at $400 million to $420 million [8] - Adjusted EPS is expected to show double-digit growth due to operating improvements and portfolio optimization, with free cash flow conversion targeted at around 50% of adjusted EBITDA and capital expenditure estimated at about $100 million [8]

-2 = "Weak, <-10% YoY:, -1 = "Soft", 0 = "Flat, -2% to 2%", 1 = "Healthy", 2 = "Strong, >10%" . (2.0) (1.5) (1.0) (0.5) - 0.5 1.0 1.5 Sales This Month Sales YTD New Orders This Month Inventories This Month Expected Sales Next Month Sourcing Difficulty (>0 = Easier) Orders Vs. Inventories Sales Acceleration (Next Month YoY - This Month) Paint Chemicals Average Source: Jefferies Proprietary Survey 100% Chart 2 - Sales Acceleration Muted, Order-to-inventory Ratio Lower Chart 3 - Market Outlook Flat For Hardwar ...

Ashland (ASH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.46%. A quarter ago, it was expected that this chemical company would post earnings of $1.17 per share when it actually produced earnings of $1.08, delivering a surprise of -7.69%.Over the last four quarters, the company ...

Exhibit 99.1 Ashland reports first quarter fiscal 2026 results and narrows full-year outlook WILMINGTON, Del., February 2, 2026 – Ashland Inc. (NYSE: ASH) today announced financial results 1 for the first quarter of fiscal year 2026, which ended December 31, 2025, and narrowed its full-year fiscal 2026 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high- quality, consumer-focused markets including pharmaceuticals, personal care and architectural coating ...

Core Insights - Ashland Inc. reported financial results for Q1 FY2026, with a sales decline of 5% year-over-year, totaling $386 million, primarily due to a divestiture and mixed demand conditions across segments [1][3][4] - The company narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to a range of $400 to $420 million, reflecting temporary impacts from operational disruptions [21][25] Financial Performance - First-quarter sales were $386 million, down from $405 million in the prior-year quarter, with a 2% reduction attributed to the Avoca divestiture [3][4] - Net loss was $12 million, an improvement from a loss of $165 million in the prior year, which was heavily impacted by a non-cash impairment [4][7] - Adjusted EBITDA was $58 million, down 5% from the prior-year quarter, with a margin of 15% [5][11] Segment Performance Life Sciences - Sales for the Life Sciences segment totaled $139 million, up 4% year-over-year, driven by resilient pharma demand and innovation [9][10] - Adjusted Operating Income for Life Sciences was $17 million, reflecting a favorable product mix and lower expenses [11] Personal Care - Personal Care sales decreased by 8% to $123 million, primarily due to the Avoca divestiture [12][15] - Adjusted EBITDA for Personal Care was $26 million, down from $30 million, with a margin of 21% [15] Specialty Additives - Specialty Additives sales were $102 million, down 11% year-over-year, impacted by weak demand in coatings and construction [16][17] - Adjusted EBITDA for Specialty Additives was $15 million, up from $13 million, indicating improved cost performance [17] Intermediates - Intermediates sales totaled $31 million, a decrease of 6% compared to the prior year, primarily due to lower pricing [18][19] Cash Flow and Financial Outlook - Cash flows from operating activities were $125 million, significantly improved from a use of $30 million in the prior-year quarter, largely due to a tax refund [7][21] - The company expects ongoing Free Cash Flow to be approximately 50% of Adjusted EBITDA, with capital expenditures around $100 million [26] Strategic Initiatives - Ashland is focused on advancing its innovation pipeline and optimizing its portfolio to enhance profitability [2][22] - The company continues to expect stronger performance in the second half of the fiscal year as operational efficiencies improve [22][27]